Ariana Pichardo-Lowden, Mark O Goodarzi, Guru Trikudanathan, Jose Serrano, Kathleen M Dungan
{"title":"轻度非坏死性急性胰腺炎后患糖尿病的风险和决定因素。","authors":"Ariana Pichardo-Lowden, Mark O Goodarzi, Guru Trikudanathan, Jose Serrano, Kathleen M Dungan","doi":"10.1097/MOG.0000000000001055","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Diabetes mellitus (DM) is relatively common following acute pancreatitis (AP), even after mild acute pancreatitis (MAP), the most frequent AP presentation, in which there is no overt beta cell injury. Post-AP related diabetes is widely misdiagnosed, resulting in potentially inappropriate treatment and worse outcomes than type 2 diabetes (T2D). Thus, it is important to understand risk across the spectrum of AP severity.</p><p><strong>Recent findings: </strong>Biological mechanisms are unclear and may include local and systemic inflammation leading to beta cell dysfunction and insulin resistance, altered gut barrier and/or gut peptides and possibly islet autoimmunity, though no studies have specifically focused on MAP. While studies examining clinical risk factors on MAP exclusively are lacking, there are studies which include MAP. These studies vary in scientific rigor, approaches to rule out preexisting diabetes, variable AP severity, diagnostic testing methods, and duration of follow-up. Overall, disease related factors, including AP severity, as well as established T2D risk factors are reported to contribute to the risk for DM following AP.</p><p><strong>Summary: </strong>Though numerous studies have explored risk factors for DM after AP, few studies specifically focused on MAP, highlighting a key knowledge gap that is relevant to the majority of patients with AP.</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"396-403"},"PeriodicalIF":2.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11305911/pdf/","citationCount":"0","resultStr":"{\"title\":\"Risk and factors determining diabetes after mild, nonnecrotizing acute pancreatitis.\",\"authors\":\"Ariana Pichardo-Lowden, Mark O Goodarzi, Guru Trikudanathan, Jose Serrano, Kathleen M Dungan\",\"doi\":\"10.1097/MOG.0000000000001055\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>Diabetes mellitus (DM) is relatively common following acute pancreatitis (AP), even after mild acute pancreatitis (MAP), the most frequent AP presentation, in which there is no overt beta cell injury. Post-AP related diabetes is widely misdiagnosed, resulting in potentially inappropriate treatment and worse outcomes than type 2 diabetes (T2D). Thus, it is important to understand risk across the spectrum of AP severity.</p><p><strong>Recent findings: </strong>Biological mechanisms are unclear and may include local and systemic inflammation leading to beta cell dysfunction and insulin resistance, altered gut barrier and/or gut peptides and possibly islet autoimmunity, though no studies have specifically focused on MAP. While studies examining clinical risk factors on MAP exclusively are lacking, there are studies which include MAP. These studies vary in scientific rigor, approaches to rule out preexisting diabetes, variable AP severity, diagnostic testing methods, and duration of follow-up. Overall, disease related factors, including AP severity, as well as established T2D risk factors are reported to contribute to the risk for DM following AP.</p><p><strong>Summary: </strong>Though numerous studies have explored risk factors for DM after AP, few studies specifically focused on MAP, highlighting a key knowledge gap that is relevant to the majority of patients with AP.</p>\",\"PeriodicalId\":50607,\"journal\":{\"name\":\"Current Opinion in Gastroenterology\",\"volume\":\" \",\"pages\":\"396-403\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11305911/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/MOG.0000000000001055\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOG.0000000000001055","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
综述的目的:糖尿病(DM)在急性胰腺炎(AP)后相对常见,即使是在轻度急性胰腺炎(MAP)后也是如此,轻度急性胰腺炎是最常见的急性胰腺炎表现,其中没有明显的β细胞损伤。与急性胰腺炎相关的糖尿病被广泛误诊,可能导致治疗不当和比 2 型糖尿病(T2D)更糟糕的结果。因此,了解 AP 严重程度范围内的风险非常重要:生物机制尚不清楚,可能包括导致β细胞功能障碍和胰岛素抵抗的局部和全身性炎症、肠道屏障和/或肠道肽的改变以及可能的胰岛自身免疫,但没有研究专门针对MAP。虽然缺乏专门针对 MAP 临床风险因素的研究,但有一些研究包括了 MAP。这些研究在科学严谨性、排除原有糖尿病的方法、不同的 AP 严重程度、诊断测试方法和随访时间等方面各不相同。总之,包括 AP 严重程度在内的疾病相关因素以及已确定的 T2D 风险因素据报道都会导致 AP 后发生 DM 的风险。总结:尽管有许多研究探讨了 AP 后发生 DM 的风险因素,但很少有研究专门关注 MAP,这凸显了与大多数 AP 患者相关的关键知识缺口。
Risk and factors determining diabetes after mild, nonnecrotizing acute pancreatitis.
Purpose of review: Diabetes mellitus (DM) is relatively common following acute pancreatitis (AP), even after mild acute pancreatitis (MAP), the most frequent AP presentation, in which there is no overt beta cell injury. Post-AP related diabetes is widely misdiagnosed, resulting in potentially inappropriate treatment and worse outcomes than type 2 diabetes (T2D). Thus, it is important to understand risk across the spectrum of AP severity.
Recent findings: Biological mechanisms are unclear and may include local and systemic inflammation leading to beta cell dysfunction and insulin resistance, altered gut barrier and/or gut peptides and possibly islet autoimmunity, though no studies have specifically focused on MAP. While studies examining clinical risk factors on MAP exclusively are lacking, there are studies which include MAP. These studies vary in scientific rigor, approaches to rule out preexisting diabetes, variable AP severity, diagnostic testing methods, and duration of follow-up. Overall, disease related factors, including AP severity, as well as established T2D risk factors are reported to contribute to the risk for DM following AP.
Summary: Though numerous studies have explored risk factors for DM after AP, few studies specifically focused on MAP, highlighting a key knowledge gap that is relevant to the majority of patients with AP.
期刊介绍:
Published bimonthly and offering a unique and wide ranging perspective on the key developments in the field, each issue of Current Opinion in Gastroenterology features hand-picked review articles from our team of expert editors. With twelve disciplines published across the year – including gastrointestinal infections, nutrition and inflammatory bowel disease – every issue also contains annotated references detailing the merits of the most important papers.